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Abstract 
There is an emerging demand for the use of molecular profiling to facilitate biomarker identification and develop‑
ment, and to stratify patients for more efficient treatment decisions with reduced adverse effects. In the past decade, 
great strides have been made to advance genomic, transcriptomic and proteomic approaches to address these 
demands. While there has been much progress with these large scale approaches, profiling at the protein level still 
faces challenges due to limitations in clinical sample size, poor reproducibility, unreliable quantitation, and lack of 
assay robustness. A novel automated capillary nano‑immunoassay (CNIA) technology has been developed. This tech‑
nology offers precise and accurate measurement of proteins and their post‑translational modifications using either 
charge‑based or size‑based separation formats. The system not only uses ultralow nanogram levels of protein but also 
allows multi‑analyte analysis using a parallel single‑analyte format for increased sensitivity and specificity. The high 
sensitivity and excellent reproducibility of this technology make it particularly powerful for analysis of clinical samples. 
Furthermore, the system can distinguish and detect specific protein post‑translational modifications that conven‑
tional Western blot and other immunoassays cannot easily capture. This review will summarize and evaluate the latest 
progress to optimize the CNIA system for comprehensive, quantitative protein and signaling event characterization. 
It will also discuss how the technology has been successfully applied in both discovery research and clinical studies, 
for signaling pathway dissection, proteomic biomarker assessment, targeted treatment evaluation and quantitative 
proteomic analysis. Lastly, a comparison of this novel system with other conventional immuno‑assay platforms is 
performed.
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Background
Advances in the molecular analysis of genes, proteins and 
metabolites have greatly improved our understanding 
of biological processes and disease, and have increased 
our ability to monitor treatment response and stratify 
patients to improve treatment efficacy. Precision medi-
cine facilitated by companion diagnostics is one of the 
driving forces accelerating the drug development process 
and improving therapeutic management [1]. For exam-
ple, targeting HER2 over-expression for breast cancer 
treatment led to the development of Herceptin (trastu-
zumab, Genentech), the first approved monoclonal anti-
body drug [2]. Another well known example is the use of 
a K-ras mutation test as a predictor of poor response to 
EGFR inhibitor treatment [3].
To enable this type of molecular profiling, concerted 
effort has been put forth in both academic and indus-
try sectors to develop and validate new technologies. In 
the past decade, many genome and transcriptome profil-
ing technologies, including next-generation sequencing, 
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single-nucleotide polymorphism (SNP), fluorescent in situ 
hybridization (FISH), and mRNA quantitation technolo-
gies, have been developed and successfully applied in areas 
from discovery and translational research to clinical prac-
tice [4–8]. However, DNA sequence information is not 
sufficient to predict the biological function of a protein, 
and gene expression does not always correlate with path-
way activation level [9, 10]. Based on UniProt, there is no 
experimental evidence at the protein level for about 38% 
out of 20,000 protein-coding human genes [11]. In a study 
of correlation between protein and mRNA abundance in 
yeast [12], Gygi et al. found that for some genes, while the 
mRNA levels were about  the same, the protein levels var-
ied by more than 20-fold. Conversely, invariant steady-state 
levels of certain proteins were observed with respective 
mRNA transcript levels that varied by as much as 30-fold. 
Post-translation modifications (PTM) of proteins, such as 
phosphorylation, acetylation and glycosylation, can alter a 
protein’s activity and affect disease development and treat-
ment response [13–15]. Thus it is critical to directly meas-
ure proteins and their activation status to confirm genomic 
predictions and monitor treatment responses.
In contrast to major advances in DNA and RNA pro-
filing, the investigation of signaling molecules at the 
protein level still faces many challenges, such as lim-
ited clinical sample size, poor reproducibility, unreliable 
quantitation, and difficulties in protocol standardization 
across different laboratories [16, 17]. There is a strong 
need to develop automated, high-throughput proteomic 
technologies for precise and accurate determination of 
protein levels and analysis of protein activation status, to 
facilitate both discovery research and clinical practice.
In this manuscript, we review the performance and 
applications of a novel capillary nano-immunoassay 
(CNIA) system (The Simple Western System™, marketed 
by ProteinSimple, CA, USA), a fully automated capillary 
electrophoresis system for characterization of proteins 
and their post-translational modifications. This new sys-
tem overcomes many of the limitations of conventional 
proteomic approaches: it offers straightforward target-
specific detection, easy operation, high quality data 
quantitation and excellent assay reproducibility using 
nanogram levels of sample. As discussed below, this tech-
nology has been successfully applied in the dissection of 
signaling pathways, assessment of proteomic biomarkers, 
and evaluation of targeted therapies.
The CNIA technology
Capillary nano-immunoassay (also named the Simple 
Western™ system by the manufacturer, Protein Simple) 
refers to a capillary-electrophoresis immunoassay sys-
tem, which offers both size-based and charge-based sepa-
ration formats. Depending on the process, samples are 
prepared with SDS-containing buffers (for size-based 
assay) or solution-phase carrier ampholytes (for charge-
based assay) and automatically loaded into small (5 cm, 
100 µm internal diameter) capillaries for electrophoretic 
separation. The CNIA system offer both size-based and 
charge-based separation formats. Figure  1 shows the 
assay scheme.
Separate by MW Separate by pI
Step 1: Load Matrix (size based assay only)
 Stacking and separation matrices are loaded in to capillaries.
Step 2: Load Sample
 ~5-40 ng protein samples, prepared with SDS-containing 
 buffers (for MW separation) or solution-phase carrier 
 ampholytes (for  IEF separation), were loaded into the 
 capillaries.
Step 3: Separate
 Proteins and florescent standards are separated by MW or 
 iso-electric point.
Step 4: Immobilize
 UV light is used to immobilize proteins to the capillary wall
 using a proprietary linking chemistry. 
Step 5: Immunoprobe
 The capillary is immunoprobed for specific proteins. Luminol 
 and peroxide are added to generate chemiluminescent light, 
 which is captured by a CCD camera.
Step 6: Quantitate 
 The digital image is analyzed and quantitative results
 are presented in the Compass software.
Figure 1 CNIA assay scheme (Courtesy of ProteinSimple).
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The size-based assay (size-CNIA) separates proteins 
based on molecular weight. The assay is performed in a 
similar manner to an SDS-PAGE gel. The protein sample 
is denatured by heat in the presence of a reducing agent 
(DTT) and is coated with SDS. The SDS coating gives the 
proteins in the sample a uniform charge-to-mass ratio. 
Because the proteins have identical charge-to-mass ratio, 
each protein’s velocity through the polymer matrix will 
depend solely on the pores in the polymer matrix and 
the protein’s radius of gyration, which is proportional to 
molecular weight.
The charge-based assay (charge-CNIA) differs from a 
traditional iso-electric focusing (IEF) gel in that the pH 
gradient is in the solution phase. An “ampholyte gradi-
ent” consisting of hundreds of zwitterionic species whose 
isoelectric points cover a range of pH is added to the 
sample mixture. When the electric field is applied, the 
ampholytes arrange themselves according to isoelectric-
point (pI) and form a pH gradient throughout the length 
of the capillary. The proteins and standards migrate 
through the gradient until they reach their pI, at which 
point they carry no net charge and cease to migrate. 
The charge-based assay is also historically referred to as 
NanoPro™ referring to the company-specific platform or 
generically as NIA (nanofluidic proteomic immunoassay) 
assays in the literature.
Electrophoresis in either format is followed by UV 
light cross-linking of the separated proteins to the cap-
illary wall through proprietary chemistry [18]. The cap-
illaries are then automatically shuttled to an adjacent 
chamber within the instrument and the capillary lumen 
is loaded and incubated successively with primary and 
HRP-tagged secondary antibodies which are flowed 
through the capillary. The resulting chemiluminescence 
signal is then detected with a CCD camera, and the digi-
tal image is analyzed with Compass software (Protein-
Simple, CA, USA). Signal strength is presented as peak 
area and quantitated. Each sample is prepared with fluo-
rescent pI (for charge-CNIA) or molecular weight (for 
size-CNIA) markers to calibrate the signal peak profile. 
Once calibrated, peaks can then be compared between 
capillaries.
CNIA assay performance
This novel analysis system offers a number of significant 
advantages over conventional immunoblot techniques as 
discussed below.
Automation and robust performance
By performing all the steps of a charge- or size-based 
Western blot in a single vessel, the system allows for a 
level of automation and robust performance that is not 
possible with conventional immunoblot techniques. 
The capillaries are ferried between different stations in 
the instrument for separation/immobilization, antibody 
incubation, detection, washing and reagent loading. This 
eliminates all handling during the run and the inconsist-
encies that can arise from manual intervention. Good 
intra-, inter-assay reproducibility has been reported with 
the system [19]. Figure 2a shows an analysis of ERK1 per-
formed by different analysts on different days. An aver-
age %CV (coefficient of variation) of less than 10% was 
observed in this example.
Sensitivity, dynamic range, turnaround time, and data 
quantitation
By taking advantage of the economies of scale in micro-
fluidics, detection sensitivity is much greater than that of 
other techniques, with results reported on samples cor-
responding to fewer than 50 cells [18].Typical CNIA runs 
load nanogram rather than microgram amount of total 
protein, and have been reported able to precisely meas-
ure sub-femtomole amount of target protein [20]. The 
CCD camera provides 10 times higher dynamic range 
measurement than film [21]. Analysis linearity over sev-
eral orders of magnitude has been reported for the sys-
tem [18, 21–23]. In the 96-capillary throughput analysis 
platforms (Peggy™, Sally™), one cycle of 12-capillary anal-
ysis can be completed in about 2–5  h. A measurement 
run of up to eight cycles, for a total of 96 samples/ana-
lytes can be done in fewer than 24 h, demonstrating a fast 
assay turn-around time. Recently released instrumenta-
tion (Wes™) is capable of running 24 samples simultane-
ously in under 3  h (see manufacture’s website for more 
detail on different analysis platforms).
The automated operating system and digital data quan-
titation allows the CNIA system to provide quantitative 
and precise measurement of signaling molecules and 
their activation status [24–30]. The system has demon-
strated more accurate and reproducible assessment of 
protein levels when compared with conventional West-
ern blot analysis and has enabled better correspondence 
of protein level and function [31–35. In a study of TGF-
β-mediated epithelial carcinogenesis [36], Kohn et  al. 
found that Smad3 gene dosage regulates the biological 
responses to TGF-β. In this study, a mere two-fold reduc-
tion in Smad3 was confirmed by precise protein measure-
ments using size-CNIA. This small reduction in protein 
levels was shown to be sufficient to promote metastasis. 
Using size-CNIA, Chen et  al. developed a method for 
measuring the absolute amount of endogenous protein at 
the picogram or sub-picogram level per nanogram of cell 
lysate [20]. The method provides an approach for precise 
and accurate assessment of protein levels to correlate 
with their functions in complex biological settings. The 
system was also demonstrated to provide quantifiable, 



















































































































Figure 2 CNIA assay performance at a glance. a Assay reproducibility. Size‑CNIA data gathered from a CNIA instrument operated by four differ‑
ent users over 4 days. Each run consisted of 11 capillaries analyzing an identical HeLa lysate with an ERK1 antibody using the standard protocol. 
Instrument software calculated ERK1 peak area in each capillary, and this was used to calculate average and %CV of peak signal (Courtesy of 
ProteinSimple). b A comparison with conventional Western blot and data quantitation. Prostate cancer LNCaP cells were treated with the indicated 
concentrations of PMA, bryostatin 1, or bryostatin 7 for 24 h. PKCβII and PKCδ were analyzed in total cell lysates by Western blot and size‑CNIA using 
anti‑PKCβII and anti‑PKCδ antibodies. Top and middle panels show representative images of conventional Western blot and CNIA respectively. Levels 
of PKCβII and PKCδ were quantitated from the CNIA data and shown in the lower panels. β‑actin signals were used as loading controls, and normal‑
ized values were expressed relative to that of the DMSO‑treated cells. Values represent the mean ± SEM of three independent experiments [38].  
c ERK isoform responses to PMA treatment detected by Charge‑CNIA. RasGRP3 transfected LNCaP cells were treated with indicated concentrations 
of PMA for 30 min. ERK1 and ERK2 signals were analyzed with charge‑CNIA using a pan‑ERK antibody. Left panel shows the peak profile for the ERK 
signals, indicating ERK phosphorylation induced by PMA treatment. Right panel shows the dose response curve of ERK isoforms to PMA treatment 
calculated from the CNIA data. Values represent the mean ± SEM of four independent experiments.
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consistent and reproducible data that are favorable for 
clinical translation [37].
With a through-put of 96 sample/analyte combinations 
in the Peggy™, Sally™ and NanoPro™ platforms of the CNIA 
system, multiple targets can be profiled simultaneously in 
one analysis run with low sample consumption. Multiple-
analyte analysis in other assays, such as multiplex bead 
assays and antibody arrays, is constrained by analyte com-
plexity and the potential impact of cross-reactivity. The 
CNIA system, however, bypasses these obstacles by per-
forming successive cycles of single-analyte analysis each 
within their separate individual capillaries. This parallel 
approach thus offers an efficient method of ‘multiplex’ 
analysis with more accurate and reliable analysis data.
Assay development and the complementary nature 
of size‑based and charge‑based formats
The Size-CNIA assays can be used to detect any protein 
for which a good antibody is available. Detection of protein 
modifications is dependent on availability of an antibody 
specific for that modification. Assay transfer from conven-
tional size-based Western blot to size-CNIA is relatively 
straight forward for most targets. Based on our experience 
with developing size-CNIA assays for about two hundred 
signaling molecule targets, more than 80% of the antibod-
ies that work in conventional size-based Western blot also 
work in size-CNIA. We observed a good correspondence 
between conventional Western blot and size-CNIA for the 
quantitation of PKC isoform down-regulation in U937 cells 
treated with phorbol esters and bryostatins (Figure 2b) [38]. 
In the charge-based configuration, using IEF as the sepa-
ration mode allows for additional levels of information to 
be obtained. Phosphorylation and other post-translational 
modification differences in a protein population lead to 
“charge variants” which can be spatially resolved in IEF. 
This allows for the simultaneous detection and accurate 
relative quantitation of these protein variants using a sin-
gle pan-specific antibody [39, 40]. The identity of the peaks/
protein variants has been established experimentally using 
modification-specific antibodies, site-directed mutagene-
sis, mass spectrometry and other techniques. See later sec-
tions for detailed examples.
The charge-CNIA has been particularly successful in 
the quantitative analysis of ERK signaling. Using a sin-
gle detection antibody, ERK1, ERK2 and their phospho-
forms can be simultaneously identified, quantitated and 
compared. Figure  2c shows the IEF profile of ERK iso-
forms treated with different concentrations of phorbol-
12-myristate-13-acetate (PMA). The changes in the 
dose response curves of individual ERK isoforms (i.e. 
the dual-phospho-ERK1/2, mono-phospho-ERK1/2, 
and non-phospho-ERK/1/2) in response to PMA treat-
ment are presented as well. Visualization of the relative 
abundance of these forms at different concentrations of 
the drug provides more detail and specific information 
about signaling molecule activation than is captured by 
conventional immunoassays.
Using the IEF system to study protein kinase G-I isoform 
expression in human ovarian cells [41], Fiscus et al. dem-
onstrated that the technology is more than 100 times more 
sensitive than the conventional Western blot in detect-
ing low abundance PKG-I expressing cancer cells. The 
technology is also able to resolve and clearly identify the 
PKG-Iα and PKG-Iβ and the phosphorylation isoforms, 
which are not distinguishable in Western blot analysis.
The development of charge-CNIA assays may not be 
as straightforward as the size-CNIA assay and is highly 
dependent on the specific antibody. In charge-CNIA 
assay, proteins are analyzed in their native forms with-
out being denatured and reduced as in size-based assays. 
However, the majority of commercially available anti-
bodies are developed and characterized by recognizing 
epitopes on denatured proteins. In addition, the data 
profiles in the charge-CNIA assays, are generally highly 
complex, requiring multiple control samples and mul-
tiple antibodies to be screened before an assay can be 
confirmed to be specific to the target. Thus, while hun-
dreds of size-CNIA assays have been developed in the 
past couple of years, the availability of validated charge-
CNIA assays is still limited. Nevertheless, when well-
validated antibodies are available, charge-CNIA assays 
are a uniquely powerful tool for generating information 
that is cumbersome or impossible to generate using other 
approaches. Antibodies developed for Human Protein 
Atlas project (http://www.proteinatlas.org/) has been 
reported may serve as a good source for charge-CNIA 
assay development [42].
Applications
The CNIA technology has been demonstrated to be ideal 
for comprehensive and quantitative protein characteri-
zation and profiling of signaling events. It holds great 
promise as a molecular diagnostic tool to facilitate preci-
sion medicine.
Charge‑CNIA, a novel platform for detailed analysis 
of signaling pathways
As noted above, when there are charge variations among 
post-translationally-modified isoforms of the target pro-
tein, the IEF separation is able to separate and discrimi-
nate the different forms, and detect them without using 
antibodies specific to the modifications [43]. This useful 
feature of the charge-CNIA has been exploited by inves-
tigators to discover novel post-translational modifica-
tions (PTM) in a number of signaling pathways and their 
association with important biological processes.
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While there were no phospho-specific Pdx1 antibodies 
available at the time, Frogne et al. used charge CNIA with 
an anti-pan-Pdx1 antibody to show that Pdx1, a tran-
scription factor for proper regulation of blood glucose 
homeostasis and pancreatic beta cell function, underwent 
post-translational modification in mammalian cells but 
not in bacterial cells [44]. They further identified that one 
of the post-translationally-modified variants is unique to 
mature beta-cells only. Together with alanine scanning 
and mass spectrometric (MS) analysis, the group deter-
mined that serine 61 is the site of the most abundant 
phosphorylation on Pdx1. In another example, Huang 
et  al. identified a new phosphorylation site on TRAF-
interacting protein with an FHA domain (TIFA) that was 
stimulated by tumor necrosis factor alpha (TNF-α) [45]. 
In conjunction with MS and in vitro kinase assay analysis, 
the phosphorylation site was confirmed to be threonine 
9. The identification of this novel threonine phosphoryla-
tion site provided new insight into the TNF-α mediated 
signaling pathway, as well as a new functional mechanism 
for the FHA domain.
Others have used the charge-CNIA to provide novel 
insights about VEGF induced c-Src phosphorylation 
changes at pY418 and pY527 [46]. Besides the overall 
VEGF induced signal change of pY418 and pY527 that is 
observed in Western blot, the assay also revealed multi-
ple additional phosphorylation isoforms that respond 
differently to VEGF stimulation, and found that the c-Src 
pY418 might be a minor fraction of the total phosphoryl-
ated c-Src comparing with pY527. The charge-CNIA has 
also proved to be powerful in the analysis of isoform-
specific phosphorylation of AKT, an important target in 
cancer therapy. Two studies demonstrated that the IEF 
separation allows simultaneously detection and measure-
ment of all three AKT isoforms with a single pan-reactive 
antibody, which enabled a more sensitive and accurate 
comparison of differential regulation roles played by the 
different isoforms [23, 47].
The high resolution of the charge-CNIA technique can 
even allow species-specific protein isoforms to be resolved 
in some cases. In a study of the effect of erlotinib on non-
small cell lung cancer (NSCLC) xenograft samples, con-
ventional Western blot analysis indicated that EGFR 
Y1068 was completely dephosphorylated upon treatment 
of erlotinib, a tyrosine kinase inhibitor, whereas ERK1/2 
appeared to be only partly dephosphorylated (Figure  3). 
However, using charge-CNIA, human ERK1 isoforms can 
be differentiated from the mouse isoforms based on their 
pI differences. Erlotinib was shown to almost completely 
inhibit ERK phosphorylation in the targeted human xeno-
graft cancer cells but had no effect on ERK phosphoryla-
tion in the surrounding mouse stromal cells [48].
Besides phosphorylation, the charge-CNIA assay is 
also able to detect other PTMs that change the charge 
of the protein and have functional consequences. Icardi 
et al. detected a pI shift of STAT3 induced by SIN3 tran-
scription regulator homolog A (Sin3a) and identified K87 
acetylation as a negative regulator of STAT3 activity [49]. 
In a similar approach, Tikhanovich and coworkers iden-
tified specific and interactive PTM patterns of phospho-
rylation, acetylation, methylation and ubiquitination of 
FOXO3 that were induced by hepatitis C virus, alcohol or 
the combination of the two, and which alter the activity 
























Figure 3 Differential ERK1/2 phosphorylation response to erlotinib treatment in HCC827 xenografts. Mice bearing xenografted tumors of HCC827 
human lung adenocarcinoma cells were treated with one dose of water or 100 mg/kg erlotinib and sacrificed 24 h after treatment. Left panel, 
charge‑CNIA of ERK phosphorylation in xenograft samples treated with water or with erlotinib. pERK1 and ppERK1 of mouse origin are resolved 
from the human isoforms and are shown in green box. Human pERK1 and ppERK1 are shown in red box, and arrows indicate that only the human 
isoform signals decrease with erlotinib treatment. The mouse stromal signal remains unchanged. Right panel, conventional Western is not able to 
detect the differential ERK isoform response between human cancer cells and mouse stroma cells and erroneously implies that ERK signaling by the 
drug is incomplete in the tumor cells [48].
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Together, these studies demonstrate that the charge-
CNIA system is able to distinguish and detect specific 
PTM isoforms that conventional Western blot and other 
immunoassays fail to identify. The technology thus pro-
vides a novel platform for in-depth study of signaling 
pathway mechanisms.
Quantitative proteomic analysis in limited patient 
specimens and real‑time molecular diagnostics
A key issue in the development of molecular-targeted 
therapy is the ability to assess whether the drug is hitting 
the target. Nanogram level sample consumption, digi-
tal data processing and quantitation, and proven assay 
reproducibility make the CNIA system appealing for 
analysis of clinical specimens to facilitate assessment of 
pharmacodynamic biomarkers and treatment evaluation. 
The technology was demonstrated to allow the measure-
ment of stem cell signals from a total of <10,000 cells, 
which contains a stem cell population of <0.2% [42].
The first CNIA application in analysis of clinical speci-
mens was reported by Fan and coworkers from Stan-
ford in 2009 [22]. In this study, multiple oncoproteins in 
human tumor samples were precisely quantified using 
charge-CNIA (NIA). Differential Myc and Bcl2 expres-
sion was identified in different types of non-Hodgkin’s 
lymphoma subtypes. Furthermore, a specific mono-
phosphorylated ERK2 signal, which correlated with 
patient response to tyrosine kinase inhibitor treatment, 
was identified in chronic myelogenous leukemia (CML) 
samples.
In a Phase I/II clinical trial, patients with higher risk 
red blood cell-dependent myelodysplastic syndrome 
(MDS) were treated with the multi-kinase inhibitor 
rigosertib [51]. Seetharam and coworkers used charge 
CNIA to show a direct correlation between changes in 
the levels of phospho-AKT2 with patient response to 
drug treatment. CNIA assays were also used to meas-
ure rigosertib treatment response in human clinical 
specimens that are too small to be analyzed by conven-
tional means, such as CD34+ cells from bone marrows 
and core biopsies from solid tumor tissues [52]. Using 
a mouse model of head and neck squamous cell carci-
noma, Hubbard and coworkers also demonstrated that 
the system allows molecular diagnostics to be performed 
longitudinally before, during and after treatment using 
a minimally invasive technique for specimen collection 
[53]. These studies indicated that the CNIA system offers 
a real-time approach to measure target pathway activities 
and response to treatment in specimen samples that are 
limited.
The high sensitivity of the system has also enabled 
the profiling of signaling molecules in other samples of 
limited availability [48, 54]. ERK activation in aberrant 
crypt foci (ACF) was measured and compared to the 
adjacent normal colonic muscosa in micro-dissected 
human clinical samples containing as little as 16 ng pro-
tein from fewer than 200 cells [55]. Other examples that 
exploit the high sensitivity of this technique include the 
analysis of target molecule response in FACS-sorted 
blast crisis leukemia stem cells derived from bone mar-
row of tyrosine kinase inhibitor-treated mice [56], 
label-retaining cancer stem cells derived from human 
hepatocellular carcinoma [57], and assessing the pS962 
PTRC/CD45 level in CD34+ cells from CML patients 
[58].
Development of pharmacodynamic and predictive 
biomarkers
Although this application has not been as fully 
exploited, the CNIA technology shows promise in 
the development of biomarkers that predict response 
to therapy [22, 51, 59, 60]. In a study of the dynamic 
phosphorylation status of signaling molecules in 
NSCLC cells treated with EGFR tyrosine kinase and 
MEK inhibitors, a specific on-target MEK response 
pattern to a MEK inhibitor was identified, which was 
not detectable by conventional Western blot [48]. The 
authors also identified a MEK2 signal that may be asso-
ciated with NSCLC cell sensitivity to the EGFR inhibi-
tor erlotinib (Figure 4). Using a charge-CNIA, Beurlet 
showed that treatment with the BCL-2 inhibitor 
ABT-7373 restored wild-type MEK phosphorylation 
patterns in mice with acute myelogenous leukemia, 
associated with extended lifespan and increased sur-
vival. [61].
Quality assessment in development and manufacture 
of biological drugs
The CNIA technology has important industrial applica-
tions as well. The CNIA platforms have been reported to 
be the choice for product quality control analysis based 
on it being a high-throughput and automated analy-
sis system, and its proven assay precision, accuracy and 
sensitivity. Michels et  al. demonstrated that the charge-
CNIA offers specificity, speed and sensitivity advantages 
over an imaged capillary isoelectric focusing platform 
when used to analyze charge heterogeneity of monoclo-
nal antibody products in early stage process develop-
ment [62]. Rustandi and colleagues applied size-CNIA 
to protein expression and identity in vaccine develop-
ment. They reported that the technology increased the 
efficiency of analytical testing and could more effectively 
guide process development [63]. The group also devel-
oped a new improved method for detection of residual 
BSA to meet quality control requirements in vaccine pro-
duction [64].
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A comparison of CNIA to other immunoassay 
technologies
Immunoassay-based analytical technologies have a long 
history and have been widely used for target-specific pro-
tein detection and quantification from discovery research 
to clinical studies. The following narrative offers a com-
parison of the CNIA system with other major immuno-
assay platforms. The advantages and challenges for each 
technology are highlighted in Table 1.
ELISA (Enzyme‑linked immunosorbent assay) 
and multiplexed bead assays
ELISA is the most widely used and highly validated 
method for protein concentration measurement. It 
remains a gold standard immunoassay for drug devel-
opment programs. A digital ELISA approach has been 
reported that detects serum proteins at sub-femtomolar 
concentrations [65]. Multiplex ELISA assays have been 
developed in recent years to quantify multiple proteins 
in complex biological samples [66, 67]. Applications of 
multiplexed assays have been mainly in biological fluid 
samples, e.g. serum and plasma. Applications in com-
plex bio-specimens, such as tissue or whole cell lysates, 
are limited due to confounding matrix effects. There 
are also challenges when optimizing analysis condi-
tions simultaneously for multiple proteins with different 
affinities for the detecting antibodies. Due to antibody 
cross-reactivity issues, most commercial kits are lim-
ited to fewer than 30 targets in a single measurement 
[68, 69]. Traditional ELISA assays usually require large 
amount of samples, and the lead time for development 
is long (usually several months to more than 1  year) 
[13]. In addition, though evidence has suggested the 
importance of protein isoforms in disease progress, 
ELISA and multiplex-bead assays are limited in access-
ing this information due to the lack of isoform specific 
antibodies to differentiate different modifications and/
or protein variants [16, 70].
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The MEK2 pI5.92 / pI5.98 ratio in erlotinib sensitive, intrinsic erlotinib resistant, 
and acquired erlotinib resistant lung adenocarcinoma cell 
pI 5.92 / pI5.98 IC50 (µM erlotinib)
Sensitive
HCC827 0.41 ± 0.01 ~ 0.05
Intrinsic resistant
H2122 4.16 ± 0.98 > 3.0
Acquired resistant
HCC827R 0.77 ± 0.03 >5.0
Figure 4 MEK2 peaks correlated with erlotinib sensitivity in NSCLC cells. a NSCLC cells with different sensitivity to erlotinib were profiled for MEK2 
activation by charge‑CNIA. A higher MEK2 peak with a pI of 5.92 (“R”) is observed in the intrinsically erlotinib resistant H2122 cells, while a higher 
MEK2 peak with a pI of 5.98 (“S”) is observed in erlotinib sensitive HCC827 cells. The MEK2 pI 5.98 “S” signal was also decreased after the HCC827 cells 
were cultured in escalating concentrations of erlotinib which led to acquired resistance to the drug. b Quantitation of relative R and S peaks in the 
three cell lines [48].
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Conventional Western blot
Combining protein separations with target-specific anti-
body probing, Western blot has been the top choice for 
studying protein levels and post-translational modifica-
tions, due to the low cost and simplicity of the technol-
ogy. However, the conventional Western blot technology 
suffers from large sample and reagent usage, time and 
labor commitment, semi-quantitative data, poor repro-
ducibility, and low throughput. Currently, Western blot 
is mainly used in discovery research and encounters dif-
ficulties in further development for pre-clinical and clini-
cal applications [69, 71].
Protein arrays
Protein arrays are somewhat analogous to chip-based 
transcriptional profiling for analysis of proteins and 
their functioning status. There are two types of protein 
arrays, antibody arrays and reverse-phase protein arrays 
(RPPA). The antibody arrays involve immobilizing 
well-characterized antibodies on a solid support which 
are then used for detecting multiple target proteins or 
PTMs in single sample. Labeled protein mixtures are 
applied to the array followed by immuno-analysis. In 
contract, multiple tissue or cell lysates, instead of anti-
bodies, are used to construct RPPAs., The arrays are 
then probed by target-specific antibodies, thus allowing 
multiple samples to be queried simultaneously for a sin-
gle target. Like CNIA protein arrays offer multiplexed 
protein profiling in low sample volumes. Protein arrays 
have been successfully applied in clinical proteomics, 
biomarker identification, therapeutic monitoring, bio-
marker discovery, and evaluation of pharmaceutical 
targets. [72–74]. Quantitative proteomic profiling of 
signaling pathways from surgical and micro-dissected 
tumor specimens and fine-needle aspirates were shown 
to be promising for guiding potential therapeutic inter-
vention strategies [73, 75, 76].
The antibody array and RPPA face several technical 
challenges compared with CNIA. Since the platforms 
cannot identify nonspecific binding of the antibod-
ies to other proteins, so rigorous antibody validation 
procedures are required to assure absolute specificity 
[10, 15, 77], Moreover, additional specific antibodies 
are needed to detect protein isoform variants [68]. As 
in multiplexed bead assays, antibody array-based pro-
tein measurements are usually limited to 30–50 targets 
due to antibody cross-reactivity [78]. RPPA has the 
advantage over CNIA that hundreds of samples can be 
analyzed in a single slide for a single target, with the 
detection sensitivities of 1000-5000 molecules/spot 
[77]. However, the technology can be expensive when 
only a small number of samples are evaluated across 
many targets.
Immunohistochemistry
Immunohistochemistry (IHC) detects endogenous pro-
teins in situ and thus provides spatial information about 
heterogeneous expression of proteins in their natu-
ral environment within a tissue that is not provided by 
bulk biochemical analysis techniques such as CNIA 
[79]. Traditional IHC analysis is the most widely used 
immunoassay for clinical tissue sample analysis and has 
demonstrated the power of biomarker analysis to drive 
clinical decisions. However, IHC data are usually semi-
quantitative and lack of reproducibility making the 
approach difficult to use when quantitative information 
is important, for example, when assessing pharmacody-
namic biomarker responses to targeted therapies. Since 
IHC data assessment primarily relies on the individual 
pathologist’s experience, it is difficult to standardize pro-
cedures when data interpretation is subjective [80].
Further improvements of the CNIA technology
As discussed in this manuscript and elsewhere, the CNIA 
technology has shown considerable promise for quanti-
tative sensitive proteomic analysis. For the future devel-
opment and translational application of the technology, 
some improvements are needed.
Expanding the range of target detection with good 
resolution
To accommodate the analysis of a broad range of protein 
size and charge, new reagents and assay conditions will 
need to be developed. In the size-based analysis platform, 
current reagents and assay conditions are optimized for 
the separation of proteins with MW between 12 and 
230  kDa. Based on our experience, when proteins with 
molecular weights lower than 20  kD, variation in esti-
mated molecular weight or low signals were observed 
for some proteins. In addition, although a new kit for 
66–440  kD protein analysis has been released (see the 
ProteinSimple website for product detail), more exten-
sive validation of the kit performance is desired. In the 
IEF system, good assay resolution and reproducibility are 
observed between pI 4–8. While this covers most pro-
teins, reduced resolution and lower assay reproducibility 
can be observed with especially low or high pI targets.
Improving signal‑to‑noise ratio in size‑CNIA
In general, straight-forward assay transfer and good data 
consistency with conventional Western blot assays has 
been observed with the size-CNIA assays. Occasionally, 
high background has been observed in the size-CNIA 
assays. This phenomenon is mostly primary antibody-
dependent. It may be solved by additional blocking of 
the capillaries, increasing the antibody dilution fac-
tor, or switching to an alternative primary antibody. We 
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have seen a higher baseline noise in the higher-sensitiv-
ity size-CNIA analysis mode that uses the newer Peggy 
Sue™ technology. Though this analysis mode offers more 
than five-fold increase in signal, in our experience, the 
higher noise level seen with some targets can jeopardize 
data quantification and assay reproducibility. Also, the 
Peggy Sue analysis mode has been observed to be sensi-
tive to climate factors, such as low humidity in the winter 
months. This analysis mode needs further development 
to restore the robustness that is an important positive 
attribute of the CNIA assays.
Peak identification for charge‑CNIA
The comprehensive in-depth information obtained 
for signaling molecule activation by the IEF system is 
exciting. However, it also raises the challenge of deter-
mining the identities of the peak components revealed 
by the system. For a complete understanding of the 
complicated peak profiles and their correlations to 
the function of signaling molecules, other technolo-
gies will need to be employed. In cases where isoform- 
and PTM-directed antibodies are available along with 
knockout cells and/or mutant constructs, peak identity 
has been determined [23, 46, 47, 50]. Mass spectrom-
etry (MS) peak identification protocols have also been 
developed and used for identification of previously 
unknown phosphorylation sites on their targets in the 
CNIA system [44, 45, 81]. For broader application, peak 
ID protocols will need to be developed for more com-
plex PTM patterns.
Integrating the CNIA technology 
with complementary proteomics approaches
It is likely that the specific advantages of many of the dif-
ferent technologies can be usefully combined in ways that 
exploit the specific strengths of each. There are reports 
of using RPPA and antibody arrays as an initial discovery 
screening to identify predictive assays that are later trans-
ferred to CNIA analysis with reduced complexity for 
potential clinical applications [82, 83]. With the further 
development and improvement of the CNIA system, it is 
expected that complementary and supplementary appli-
cations of this new technology with other immunoassay 
platforms will emerge.
Like other immunoassays, antibody performance 
and availability in many circumstance may limited the 
applications of CNIA assays. In the past decade, the 
field of MS-based proteomics has grown tremendously. 
MS-based multiple reaction monitoring (MRM) assays 
provide targeted, quantitative and multiplexed analy-
sis of proteins and respective PTM isoforms without 
the requirement for an antibody [84, 85]. The MS tech-
nology has demonstrated to be a powerful discovery 
platform. Though more complicated sample process-
ing and data analysis are involved with MS assays, and 
more sophisticated expertise is required to operate the 
system, MRM–MS assays can be rapidly configured 
for verification of protein biomarker candidates before 
further moving to clinical-grade immunoassays. An 
in-depth discussion of the MS technology is beyond 
the scope of this review. Interested readers may refer 
to Libeler’s recent review [84] about MRM for more 
information. As mentioned in the previous session that 
MS protocols have been used as a strategy to detect the 
detail identity of PTM isoforms revealed by the charge-
CNIA assays [44, 45, 81]. Integrating the different analy-
sis methods will allow a more comprehensive study of 
proteins and their functioning mechanisms and will 
help translate the discovery research data into clinical 
practice.
Conclusions
As reviewed here, the CNIA system provides comprehen-
sive and quantitative analysis for protein characterization 
and profiling of signaling events. The automated system 
offers easy operation, precise and accurate measurement 
of proteins and their post-translational modifications and 
a fast turn-around time. The capillary platform allows 
functional proteomic analysis to be performed with lim-
ited sample, such as from stem cells, primary cells, fine 
needle aspirates, micro-dissection samples and other 
patient specimens. Good intra-assay, inter-run and inter-
person data reproducibility have been observed with the 
system, which enables assay standardization across mul-
tiple testing sites.
With the further validation of CNIA assays and 
development of the technology, it is expected that a 
growing number of applications in both discovery 
research and clinical practice for signaling pathway 
dissection, proteomic biomarker assessment, and tar-
geted therapy evaluation. The high reproducibility and 
data precision of the technique mean the technology 
can be readily adapted for use in CLIA-certified set-
tings. Complemented with other genome, transcrip-
tome and additional protein analysis technologies, the 
CNIA technology shows great promise for developing 
pathway specific diagnostics for better treatment group 
stratification and acceleration of drug development and 
disease management.
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